Antibody Drugs: Technologies and Global Markets

February 06, 2012

 

Wellesley, Mass. – According to a new technical market research report, ANTIBODY DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (BIO016H) from BCC Research (www.bccresearch.com), the global market for antibodies was valued at nearly $44.7 billion in 2011 and is expected to increase to $57.7 billion in 2016, a five-year compound annual growth rate (CAGR) of 5.3%.

The global market for antibodies can be separated into the U.S. and the rest of the world. 

The U.S., worth $20.1 billion in 2011, is expected to increase at a CAGR of 6.4% to reach $27.4 billion in 2016.

The rest of the world, worth $24.5 billion in 2011, should reach $30.3 billion in 2016, a CAGR of 4.3%.

An antibody is a special kind of blood protein synthesized in lymphoid tissue in response to the presence of a specific protein. Antibodies circulate in the plasma to attack these specific proteins, called antigens, which are found on the surface of foreign cells. The antibody attacks the antigen and renders it harmless. To successfully recognize and protect the body from foreign substances, millions of antibodies are created, each one having the ability to target a unique antigen.

Therapeutic monoclonal antibodies (mAbs) represent the largest and one of the fastest-growing classes of biopharmaceutical products by sales in the U.S. and throughout the world. Of the top 20 drugs by sales throughout the world today, five are mAbs.

Globally, there are more than 300 mAb products in clinical-stage development by more than 100 companies for the treatment of virtually every debilitating disease. Hundreds more therapeutic mAbs are in earlier preclinical and discovery stages of development as well.

This study will be of interest to those working in the biotechnology and pharmaceutical industries and related life science, drug discovery, and diagnostic test manufacturing companies, as well as all those interested or actively working in drug research.

SUMMARY FIGURE
GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES, 2009-2016
($ MILLIONS)
GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES,  2009-2016
To Contact us, click here  help


Source: BCC Research

Antibody Drugs: Technologies and Global Markets( BIO016H )
Publish Date: Feb 2012    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.